Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.79 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.53 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29184696 | 0.98 | FFAR1 (0.76) | FFAR1KEAP1HTTFFAR4CA1 | |
| Hydrochloric Acid SCHEMBL28568409 | 0.98 | FFAR1 (0.76) | FFAR1KEAP1HTTFFAR4CA1 | |
| SCHEMBL1841290 | 0.94 | FFAR1 (0.71) | FFAR1KEAP1HTTFFAR4 | |
| Trifluoroacetic Acid SCHEMBL7394332 | 0.92 | FFAR1 (0.69) | FFAR1KEAP1HTTFFAR4CA1 | |
| SCHEMBL7011662 | 0.90 | FFAR1 (0.67) | FFAR1KEAP1HTTFFAR4CA1 | |
| Butyric Acid SCHEMBL30807147 | 0.89 | FFAR1 (0.65) | FFAR1KEAP1HTTFFAR4 | |
| SCHEMBL69746 | 0.88 | FFAR1 (0.81) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL10853169 | 0.88 | FFAR1 (0.64) | FFAR1KEAP1HTTFFAR4SLC5A1 | |
| SCHEMBL655425 | 0.87 | SMN1; SMN2 (0.67) | FFAR1HTT | |
| Hydrochloric Acid SCHEMBL25264643 | 0.85 | FFAR1 (0.77) | FFAR1KEAP1FFAR4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 843 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036772-A | Synthesis method of beta-pinacol borate-alkyl ketone compound | 陇东学院 | 2026-05-15 | — | — | CN | claimed |
| US-12497636-B2 | Recombinant Saccharomyces cerevisiae cells for cannabinoid production | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-12-16 | — | — | US | claimed |
| CN-120137643-A | Composite material, preparation method thereof, photoelectric device and display device | 广东聚华新型显示研究院 | 2025-06-13 | — | — | CN | claimed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | claimed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| CN-114350062-B | High-rigidity low-yield polypropylene torsion film and preparation method thereof | 界首市天鸿新材料股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2022-06-23 | — | — | US | claimed |
| CN-113683805-B | Preparation method of cross-linked imidazole functionalized polyether sulphone anion exchange membrane containing benzimidazole structure | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-114350062-A | High-rigidity low-yield polypropylene tangle film and preparation method thereof | 界首市天鸿新材料股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113683805-A | Preparation method of cross-linked imidazole functionalized polyether sulphone anion exchange membrane containing benzimidazole structure | 浙江工业大学 | 2021-11-23 | — | — | CN | claimed |
| CN-106748725-A | A kind of preparation method of the fluorobenzene propionic acid of 4 chlorine 2 | 贵州大学 | 2017-05-31 | — | — | CN | claimed |
| CN-101268049-A | Novel piperidine derivatives | ASTRAZENECA AB (SE) | 2008-09-17 | — | — | CN | claimed |
| EP-1620457-A2 | INDUCERS OF RECOMBINANT PROTEIN EXPRESSION | Immunex Corporation (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040265964-A1 | Inducers of recombinant protein expression | IMMUNEX CORPORATION | 2004-12-30 | — | — | US | claimed |
| WO-2004096833-A2 | INDUCERS OF RECOMBINANT PROTEIN EXPRESSION | IMMUNEX CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| EP-1129076-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000029380-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2000-05-25 | — | — | WO | claimed |
| US-5981521-A | USEFUL FOR TREATING VARIOUS HORMONE DEPENDENT DISEASES, INCLUDING PROSTATE CANCER, ENDOMETRIOSIS, UTERINE FIBROIDS, PRECOCIOUS PUBERTY, BENIGN PROSTATE HYPERTROPY AND IN VITRO FERTILIZATION | ABBOTT LABORATORIES (US) | 1999-11-09 | — | — | US | claimed |
| US-5358939-A | For applying to soils, seeds, plants, or for storage of cereal grains | ROHM AND HAAS COMPANY (US) | 1994-10-25 | — | — | US | claimed |
| EP-0576201-A2 | Fungicidal 1,2,4-triazoles | ROHM AND HAAS COMPANY (US) | 1993-12-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | HSD11B1, HSD11B2, CYP11B1 | FFAR1 695/4885KEAP1 1504/4885HTT 2603/4885 |
| US-20040265964-A1 | Inducers of recombinant protein expression | AADAC, CRYAA, PMAIP1 | FFAR1 2596/4885KEAP1 4086/4885HTT 1033/4885 |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | HSD11B1, HSD11B2, HSD17B1 | FFAR1 623/4885KEAP1 1272/4885HTT 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.